PHILADELPHIA, June 05, 2024 — Accelerated Biosciences Corp. (“Accelerated Bio”) is excited to announce a strategic partnership with Agathos Biologics aimed at developing ethically derived cell lines from Accelerated Bio’s human Trophoblast Stem Cells (“hTSC”) for manufacturing complex biologics. This collaboration marks a significant step towards replacing cell lines derived from aborted fetal tissue, including the widely used Human Embryonic Kidney cell line (HEK293), with new, ethically sourced human cell lines. [Read more…]
Gameto Announces New Data Demonstrating Clinical-Grade Manufacturing of In Vitro Maturation Solution for Fertility Care
Manuscript demonstrates Gameto’s manufacturing process resulted in ovarian support cells of improved efficacy, quality and safety for in vitro maturation applications
NEW YORK, May 8, 2024 — Gameto, a female-led biotechnology company with a mission to redefine women’s healthcare, announced new research outlining the cellular engineering and manufacturing techniques underlying Fertilo, their novel investigational in vitro maturation (IVM) solution containing engineered ovarian support cells (OSCs) to mature eggs outside of the body. These data underscore that Gameto’s quality by design strategic product development supports the manufacturing of OSC-IVM for clinical and commercial use. [Read more…]
Further CYP-001 GvHD Clinical Data Published in Nature Medicine
Two-year overall survival rate in patients with steroid-resistant acute GvHD was 60%
Melbourne, Australia; 22 May 2024 — Cynata Therapeutics Limited (ASX: “CYP”, “Cynata”, or the “Company”), a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to announce the publication of two-year follow-up data of CYP-001 in patients with steroid-resistant acute graft versus host disease (SR-aGvHD) in the prestigious peer-reviewed journal Nature Medicine.
CYP-001 is Cynata’s Cymerus™ off-the-shelf iPSC[i]-derived MSC[ii] product for intravenous infusion, which is being investigated as a potential immune modulating treatment. [Read more…]
AABB Releases New Resources and Initiatives For its Certified Advanced Biotherapies Professional (CABP) Program
May 1, 2024, Bethesda, MD – The Association for the Advancement of Blood & Biotherapies (AABB) is pleased to announce several new offerings as part of its Certified Advanced Biotherapies Professional (CABP) credentialing program. These updates, released to make the CABP program more accessible to biotherapies professionals and organizations, include: [Read more…]
Century Therapeutics Raises $60 Million, Acquires Clade Therapeutics, and Expands Pipeline of Allogeneic, iPSC-Derived Cellular Therapies
Century is pursuing additional autoimmune disease regulatory filings for its iPSC derived iNK cell therapy, CNTY-101, beyond CALiPSO-1 trial in SLE, based on the potential of its differentiated profile
Private placement of $60 million led by Bain Capital Life Sciences supports expansion in autoimmune disease; Reinforcing cash runway into 2026
Acquisition of Clade Therapeutics strengthens Century’s position as a leader in allogeneic, iPSC-derived cell therapy through enhancement of pipeline and next generation Allo-EvasionTM platform
Newly expanded pipeline incorporates three additional preclinical-stage programs from Clade’s αβ iT platform spanning across cancer and autoimmune diseases
- « Previous Page
- 1
- …
- 26
- 27
- 28
- 29
- 30
- …
- 117
- Next Page »